SpinChip Diagnostics AS

Carnegie Investment Bank is proud to have acted as Sole Bookrunner in connection with SpinChip Diagnostics AS’ successful NOK 65 million private placement.

SpinChip Diagnostics is a medical device company who has developed a proprietary platform focused on in-vitro diagnostics (IVD) to develop diagnostic tests for acute and chronic cardiac indications where test results are rapidly needed to provide patients with life-saving treatments. The diagnostics platform has, through internal trials, already demonstrated the ability to match the most advanced high-sensitive laboratory diagnostic analyzers, meaning it can contribute to faster reliable triaging and facilitate earlier appropriate treatment of patients. SpinChip is now preparing for clinical trial activities, including clinical performance studies, to gather sufficient data to apply for CE-marking.

Carnegie congratulates Chair Åse Aulie Michelet, CEO Morten Jurs, CSO Stig Morten Borch, the shareholders and the rest of the SpinChip team with the successful transaction. We look forward to continuing our support of SpinChip going forward.

Related articles

Schibsted
Investment Banking

Schibsted

Acquisition of 9.99% in FINN – NOK 2.5 billion Carnegie Investment Bank acted as financial advisor to...

BerGenBio ASA
Investment Banking

BerGenBio ASA

Carnegie Investment Bank is proud to have acted as manager in the exercise of warrants in...

Oncoinvent AS
Investment Banking

Oncoinvent AS

Carnegie Investment Bank is proud to have acted as Joint Bookrunner in connection with Oncoinvent AS’ NOK...